Literature DB >> 17361333

The combined effects of multiple chemotherapeutic agents for malignant glioma cells.

Takao Nakagawa1, Toshihiko Kubota, Kazunori Ido, Takahiro Sakuma, Ken Matsuda.   

Abstract

The prognosis of malignant gliomas remains poor, despite the progress of surgery and radiotherapy. Chemotherapy has been shown to prolong an overall survival, but the benefits are still small. To overcome this situation, the optimal regimen of antineoplastic agents is required. In the present study, we investigated the effect of the association of five chemotherapeutic drugs, including ACNU, CBDCA, CDDP, VCR, and VP-16, on cell survival of U87, YKG1, A172, and U251 human glioma cell lines, using median-effect analysis. A synergistic effect was obtained by treatment involving the association of VP-16 with ACNU or CDDP among the combinations of two drugs, and the association of ACNU, CBDCA, and VP-16 in the combination of three drugs. This preclinical screening using median-effect analysis supports the design of clinical trials by indicating more effective combinations of antineoplastic agents for malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361333     DOI: 10.1007/s11060-007-9357-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.

Authors:  David N Korones; Amy Smith; Nicholas Foreman; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

2.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

3.  Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Eur J Biochem       Date:  1981-03-16

4.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

Authors:  Ulrich Herrlinger; Johannes Rieger; Dorothee Koch; Simon Loeser; Britta Blaschke; Rolf-Dieter Kortmann; Joachim P Steinbach; Thomas Hundsberger; Wolfgang Wick; Richard Meyermann; Ta-Chih Tan; Clemens Sommer; Michael Bamberg; Guido Reifenberger; Michael Weller
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

5.  Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.

Authors:  M Barrié; C Couprie; H Dufour; D Figarella-Branger; X Muracciole; K Hoang-Xuan; D Braguer; P M Martin; J C Peragut; F Grisoli; O Chinot
Journal:  Ann Oncol       Date:  2005-04-27       Impact factor: 32.976

Review 6.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.

Authors:  Takashi Shingu; Kazuo Yamada; Nobumasa Hara; Kouzo Moritake; Harumi Osago; Masaharu Terashima; Takeshi Uemura; Toshiki Yamasaki; Mikako Tsuchiya
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.

Authors:  A J Janss; A Cnaan; H Zhao; A Shpilsky; C Levow; L Sutton; P C Phillips
Journal:  Anticancer Drugs       Date:  1998-08       Impact factor: 2.248

9.  Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.

Authors:  Marco Balzarotti; Emilio Ciusani; Chiara Calatozzolo; Danilo Croci; Amerigo Boiardi; Andrea Salmaggi
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

10.  Synergistic interaction between paclitaxel and 8-chloro-adenosine 3',5'-monophosphate in human ovarian carcinoma cell lines.

Authors:  H M McDaid; P G Johnston
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more
  3 in total

1.  Which therapy works better in choroid plexus carcinomas?

Authors:  Su G Berrak; Diane D Liu; Brigitte Wrede; Johannes E Wolff
Journal:  J Neurooncol       Date:  2010-10-26       Impact factor: 4.130

2.  Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas?

Authors:  Luni Emdad; Zulekha A Qadeer; Lucia B Bederson; Harini P Kothari; Mahmud Uzzaman; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

3.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.